Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity
- 8 February 2018
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 35 (3) , 56
Abstract
This paper aims to investigate the immunoinhibitory properties of a lymph nodes-targeting suppressive oligonucleotide (ODN) for the potential treatment of autoimmune diseases or chronic inflammation.Keywords
Funding Information
- American Cancer Society (11-053-01-IRG)
This publication has 31 references indexed in Scilit:
- IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasisClinical Immunology, 2017
- Design of Polyelectrolyte Multilayers to Promote Immunological ToleranceACS Nano, 2016
- From sewer to saviour — targeting the lymphatic system to promote drug exposure and activityNature Reviews Drug Discovery, 2015
- Phosphorothioate Oligonucleotides: Effectiveness and ToxicityCurrent Drug Targets, 2014
- Structure-based programming of lymph-node targeting in molecular vaccinesNature, 2014
- TLR-dependent T cell activation in autoimmunityNature Reviews Immunology, 2011
- Classification, Mechanisms of Action, and Therapeutic Applications of Inhibitory Oligonucleotides for Toll-Like Receptors (TLR) 7 and 9Mediators of Inflammation, 2010
- Repetitive Elements in Mammalian Telomeres Suppress Bacterial DNA-Induced Immune ActivationThe Journal of Immunology, 2003
- Toll-Like ReceptorsAnnual Review of Immunology, 2003
- Active Macromolecule Uptake by Lymph Node Antigen-Presenting Cells: A Novel Mechanism in Determining Sentinel Lymph Node StatusAnnals of Surgical Oncology, 2000